CN101365486B - 使用抗egfr和抗her2抗体的联合治疗 - Google Patents
使用抗egfr和抗her2抗体的联合治疗 Download PDFInfo
- Publication number
- CN101365486B CN101365486B CN2006800503998A CN200680050399A CN101365486B CN 101365486 B CN101365486 B CN 101365486B CN 2006800503998 A CN2006800503998 A CN 2006800503998A CN 200680050399 A CN200680050399 A CN 200680050399A CN 101365486 B CN101365486 B CN 101365486B
- Authority
- CN
- China
- Prior art keywords
- egfr
- her2
- antibody
- cancer
- mab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Abstract
Description
mAb | 处理a | 增大倍数b | %无肿瘤小鼠 |
-50 | CMTT+M | 8.0±4.04.9±2.16.4±4.40.7±0.5 | 00025(2/8) |
-200 | CMTT+M | 21.3±7.04.3±2.85.5±2.10.8±0.3 | 00060(3/5) |
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06000107.0 | 2006-01-04 | ||
EP06000107 | 2006-01-04 | ||
PCT/EP2006/012133 WO2007076923A1 (en) | 2006-01-04 | 2006-12-15 | Combination therapy using anti-egfr and anti-her2 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101365486A CN101365486A (zh) | 2009-02-11 |
CN101365486B true CN101365486B (zh) | 2012-10-31 |
Family
ID=37876938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800503998A Expired - Fee Related CN101365486B (zh) | 2006-01-04 | 2006-12-15 | 使用抗egfr和抗her2抗体的联合治疗 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20090214541A1 (zh) |
EP (1) | EP1968633B2 (zh) |
JP (1) | JP2009522316A (zh) |
KR (1) | KR20080110987A (zh) |
CN (1) | CN101365486B (zh) |
AR (1) | AR059127A1 (zh) |
AU (1) | AU2006332212B8 (zh) |
BR (1) | BRPI0620888A2 (zh) |
CA (1) | CA2636074A1 (zh) |
EA (1) | EA015173B1 (zh) |
MX (1) | MX2008008564A (zh) |
WO (1) | WO2007076923A1 (zh) |
ZA (1) | ZA200806723B (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP2335728A1 (en) | 2001-05-11 | 2011-06-22 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
CN104043123B (zh) | 2007-01-25 | 2019-08-13 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
AU2008227123B2 (en) | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
MX2010001757A (es) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. |
CA2710680C (en) * | 2007-12-26 | 2018-10-16 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
PE20110593A1 (es) | 2008-09-03 | 2011-09-10 | Genentech Inc | Anticuerpos multiespecificos |
EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
WO2010120514A2 (en) * | 2009-03-31 | 2010-10-21 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
EP2507381A4 (en) * | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS |
US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
EP2710038B1 (en) | 2011-05-16 | 2018-01-17 | Yeda Research and Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
EP2844675B1 (en) | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
US10562974B2 (en) | 2013-03-13 | 2020-02-18 | University Of Kentucky Research Foundation | Methods of administering IgG1 antibodies and methods of suppressing angiogenesis |
WO2014139131A1 (en) * | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
DK3019533T3 (da) * | 2013-07-11 | 2020-03-23 | Scripps Research Inst | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf |
WO2015073721A1 (en) | 2013-11-13 | 2015-05-21 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
PT3186283T (pt) * | 2014-08-29 | 2020-02-21 | Hoffmann La Roche | Terapêutica combinada de imunocitocinas de variante de il-2 dirigidas ao tumor e anticorpos contra pd-l1 humano |
CN104991065B (zh) * | 2015-07-07 | 2017-01-11 | 复旦大学附属金山医院 | 一种用于诊断乳腺癌的三联标志物及其应用 |
JP2018062980A (ja) * | 2016-10-12 | 2018-04-19 | 株式会社ジェイテクト | ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置 |
MX2019007801A (es) * | 2016-12-28 | 2019-10-30 | Genentech Inc | Tratamiento de cáncer avanzado con expresión de her2. |
CN117915950A (zh) * | 2021-08-06 | 2024-04-19 | 甘李药业股份有限公司 | 一种多特异性抗体及其用途 |
CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270765B1 (en) * | 1995-06-07 | 2001-08-07 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
SI1549344T1 (sl) | 2002-10-10 | 2015-05-29 | Merck Patent Gmbh | FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1 |
AU2005211890B2 (en) * | 2004-02-12 | 2011-07-28 | Merck Patent Gmbh | Highly concentrated liquid formulations of anti-EGFR antibodies |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
-
2006
- 2006-12-15 BR BRPI0620888-6A patent/BRPI0620888A2/pt not_active IP Right Cessation
- 2006-12-15 JP JP2008548941A patent/JP2009522316A/ja active Pending
- 2006-12-15 KR KR1020087019157A patent/KR20080110987A/ko not_active Application Discontinuation
- 2006-12-15 US US12/086,725 patent/US20090214541A1/en not_active Abandoned
- 2006-12-15 CA CA002636074A patent/CA2636074A1/en not_active Abandoned
- 2006-12-15 MX MX2008008564A patent/MX2008008564A/es not_active Application Discontinuation
- 2006-12-15 AU AU2006332212A patent/AU2006332212B8/en not_active Ceased
- 2006-12-15 CN CN2006800503998A patent/CN101365486B/zh not_active Expired - Fee Related
- 2006-12-15 EP EP06829664.9A patent/EP1968633B2/en not_active Not-in-force
- 2006-12-15 EA EA200870141A patent/EA015173B1/ru not_active IP Right Cessation
- 2006-12-15 WO PCT/EP2006/012133 patent/WO2007076923A1/en active Application Filing
-
2007
- 2007-01-03 AR ARP070100020A patent/AR059127A1/es unknown
-
2008
- 2008-08-01 ZA ZA200806723A patent/ZA200806723B/xx unknown
-
2014
- 2014-11-10 US US14/536,854 patent/US9522956B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270765B1 (en) * | 1995-06-07 | 2001-08-07 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
Also Published As
Publication number | Publication date |
---|---|
EP1968633A1 (en) | 2008-09-17 |
CA2636074A1 (en) | 2007-07-12 |
EP1968633B1 (en) | 2014-02-12 |
ZA200806723B (en) | 2009-09-30 |
US9522956B2 (en) | 2016-12-20 |
AU2006332212B2 (en) | 2013-03-28 |
EA200870141A1 (ru) | 2009-02-27 |
US20150132308A1 (en) | 2015-05-14 |
BRPI0620888A2 (pt) | 2011-11-29 |
EP1968633B2 (en) | 2017-11-01 |
KR20080110987A (ko) | 2008-12-22 |
US20090214541A1 (en) | 2009-08-27 |
WO2007076923A1 (en) | 2007-07-12 |
AR059127A1 (es) | 2008-03-12 |
CN101365486A (zh) | 2009-02-11 |
MX2008008564A (es) | 2009-01-29 |
AU2006332212A1 (en) | 2007-07-12 |
AU2006332212B8 (en) | 2013-05-30 |
EA015173B1 (ru) | 2011-06-30 |
JP2009522316A (ja) | 2009-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101365486B (zh) | 使用抗egfr和抗her2抗体的联合治疗 | |
KR101088661B1 (ko) | Erb-b1 수용체를 표적으로 하는 약학적 조성물 | |
CA2436326C (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
CN102884084B (zh) | 抗her2抗体及组合物 | |
JP2014510047A (ja) | 前立腺癌治療のための抗アルファ−vインテグリン抗体 | |
Krzemieniecki et al. | Targeting of solid tumors and blood malignancies by antibody-based therapies—EGFR-pathway as an example | |
EP2236139A1 (en) | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor | |
ZA200503706B (en) | Pharmaceutical compositions directed to Erb-B1 receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: UNIVERSIT MONTPELLIER 1 NATIONAL HEALTH AND MEDICAL TREATMENT INSTITUTE REGIONAL ANTICANCER CENTER Effective date: 20130506 Owner name: NATIONAL HEALTH AND MEDICAL TREATMENT INSTITUTE Free format text: FORMER OWNER: MERCK PATENT GMBH Effective date: 20130506 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130506 Address after: France Patentee after: National Health and Medical Treatment Institute Address before: Darmstadt Patentee before: Merck Patent GmbH Patentee before: Universite Montpellier 1 Patentee before: National Health and Medical Treatment Institute Patentee before: Regional Anticancer Center |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121031 Termination date: 20151215 |
|
EXPY | Termination of patent right or utility model |